SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of ...

The new approval allows patients to transition to a single 200mg subcutaneous injection once every 4 weeks, following completion of the induction phase.

The Election Commission (EC) on Monday (October 13, 2025) issued a notification for the second phase of Assembly elections in Bihar to be held on November 11, beginning the process of filing of ...

This Phase 3 clinical trial on BioChaperone® Lispro (THDB0206 injection) conducted in China in people with Type 1 Diabetes, successfully demonstrated, in comparison with standard of care Humalog®: Non ...

HONOLULU (KHON2) – The next phase of Honolulu’s Skyline rail is set to open Thursday, Oct. 16, adding four new stops from Aloha Stadium to Middle Street. Around the clock testing starts for phase 2 of ...

Mumbai: Work on Metro Line 2—also known as the Yellow Line—which will connect Mumbai’s eastern and western suburbs, is progressing steadily, according to Mumbai Metropolitan Region Development ...

ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a ...

Artemis Gold has approved plans to increase throughput at its Blackwater mine in British Columbia, announcing a 33% expansion of the Phase 1 processing plant and placing orders for key equipment ahead ...

Arcus Biosciences recently announced initial overall survival results from the Phase 2 EDGE-Gastric study, showing a median overall survival of 26.7 months for domvanalimab plus zimberelimab with ...

Prediction of Treatment Efficacy in Locally Advanced Rectal Cancer Using a Clinical and Magnetic Resonance Imaging–Based Radiomics-Immunological Model for Total Neoadjuvant Therapy Fifty patients were ...

EMERYVILLE, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...